SIRPA and neoplasm: At 20 weeks from treatment initiation, tumor number and volume per colon were significantly reduced in mice treated with anti‐SIRPα mAb when compared with those in mice treated with isotype‐matched control Ab (P = 0.013, P = 0.001) (Figure 7C,D).